Impact ledger
C4 Therapeutics, Inc. (CCCC): the developments shaping its investment case
Follow the evidence affecting C4 Therapeutics, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research C4 Therapeutics, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-26 · 3 reports
C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data
Channel: Positive clinical trial data for lead candidate, increasing probability of success and future revenue potential.
Bullish· 1-3m
Event impact log
3 events mapped to CCCC since 2026-09-26. Evidence through 2026-09-26.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | Positive clinical trial data for lead candidate, increasing probability of success and future revenue potential. | Bullish | 1-3m | 0.80 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | Direct clinical trial outcome for lead candidate, validating platform technology. | Bullish | 1-3m | 0.80 |
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data | Direct clinical trial success for lead candidate, de-risking development pathway, potential for future partnerships/licensing. | Bullish | 1-3m | 0.80 |
Continue this research
Build your C4 Therapeutics, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the CCCC entity page →